What do Gaucher’s disease, gout, and amyloid plaques have in common? For researchers at Mass General, each of them may shed light on the causes and treatment of Parkinson’s disease.
15 Parkman Street
Boston, MA 02114-3117
- MD, University of Pennsylvania School of Medicine
- Residency, Massachusetts General Hospital
- Residency, University of Chicago Hospitals
American Board Certifications
- Neurology, American Board of Psychiatry and Neurology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Growdon founded the Massachusetts Alzheimer's Disease Research Center (http://madrc.mgh.harvard.edu) funded by the National Institute on Aging and currently serves as the Director of the Memory Disorders Unit, which is the clinical arm of the Center. He is also Director of the Movement Disorders Unit, which is the clinical unit for the MGH Udall Center of Excellence for Parkinson Disease Research funded by the National Institute for Neurologic Diseases and Stroke. His research interests center on the clinical neurology and neuropharmacology of Alzheimer and Parkinson diseases, along with efforts to uncover biologic markers of these disease that could lead to improved diagnostic accuracy and treatment.
1. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathias CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-910.
2. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:209-222.
- Staff Story
- Oct | 28 | 2019
In a Grand Rounds presentation titled "Dementia Comes to Parkinson Disease," Dr. Growdon discussed a series of studies examining why patients with Parkinson disease often have both motor symptoms and cognitive problems, often progressing to a full dementia.